Tissue-derived tissuegenic implants, and methods of fabricating and using same

Patent metadata

Field	Value
Publication number	US-10130736-B1
Application number	US-201514933176-A
Country	US
Kind code	B1
Filing date	Nov 5, 2015
Priority date	May 14, 2010
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

The disclosure provides implants containing a plurality of particles containing at least one population of viable osteogenic cells adherent to and resident in an osteoconductive matrix or at least one viable population of osteogenic cells caused to be in contact with the osteoconductive matrix; methods of fabricating the implants; and use of the implants in bone repair. The implant further contains an osteoinductive component. An example of an osteoinductive component is a demineralized bone matrix in the form of particles or fibers.

First claim

What is claimed is:

1. A composition for implantation in a patient, consisting essentially of:
cancellous bone particles, wherein the cancellous bone particles have osteoconductive properties;
wherein the cancellous bone particles have viable endogenous osteogenic cells; and
demineralized cortical bone fibers, wherein the demineralized cortical bone fibers have osteoinductive properties;
wherein a sufficient amount of the demineralized cortical bone fibers results in the composition having improved cohesion compared to a composition consisting of less than a sufficient amount of demineralized cortical bone fibers and no other carrier.

2. The composition according to claim 1 , wherein the demineralized bone fibers have elongated shapes.

3. The composition according to claim 2 , wherein the demineralized bone fibers have a maximum dimension in a range of about 1 mm to about 10 mm before demineralization.

4. The composition according to claim 3 , wherein the maximum dimension of the demineralized bone fibers is about 6 mm, about 7 mm, about 8 mm or about 9 mm before demineralization.

5. The composition according to claim 3 , wherein the demineralized bone fibers have a minimum dimension in a range of about 5 μm to about 300 μm before demineralization.

6. The composition according to claim 1 , wherein the demineralized bone fibers are mixed with the cancellous bone particles in a ratio of about 60% demineralized bone fibers to about 40% cancellous bone particles.

7. The composition according to claim 1 , wherein the demineralized bone fibers are allogeneic to the patient.

8. The composition according to claim 1 , wherein the cancellous bone particles and the demineralized bone fibers are allogeneic to the patient.

9. The composition according to claim 1 , wherein the composition is osteogenic and is not immunologically reactive after implantation in the patient.

10. The composition according to claim 1 , wherein the endogenous osteogenic cells include a population of viable osteoprogenitor cells.

11. The composition according to claim 1 , wherein the endogenous osteogenic cells are immune privileged.

Assignees

• Musculoskeletal Transplant Foundation

Inventors

• Semler Eric
• Callahan Alex
• Canales Joed
• Carroll Katrina
• Dasgupta Anouska
• Shikhanovich Roman

Classifications

• A61L27/3687

  characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents · CPC title

• A61L27/3834

  Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title

• A61L2430/38

  for reconstruction of the spine, vertebrae or intervertebral discs · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title